TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00941603
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets; placebo administered once daily during the 5-week single-blind placebo run-in and diet stabilization period and during the 8 week double-blind treatment period.
Study: NCT03968445
Drug: [18F]DPA-714-PET/MRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]DPA-714-PET/MRI
Study: NCT00004346
Drug: chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004346
Drug: lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01120327
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02289755
Drug: ALLN-177
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALLN-177 is orally administered oxalate decarboxylase (OxDc). The goal of oral therapy with ALLN-177 is to enzymatically degrade both dietary oxalate and endogenously produced oxalate secreted in the gastrointestinal tract resulting in decreased absorption and reduced urinary oxalate excretion.
Study: NCT02682264
Drug: CB-03-01 cream, 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortexolone 17α-propionate (USAN/INN: clascoterone) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
Study: NCT01206595
Drug: SKY0402
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of SKY0402 administered as a nerve block
Study: NCT01595750
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 500 mcg , 12 weeks of treatment
Study: NCT02116972
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 5 mL IA injection
Study: NCT00002466
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002466
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01329549
Drug: BIBF 1120 (high) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBF 1120 twice daily along with standard therapy of PLD + CBDCA
Study: NCT01329549
Drug: BIBF 1120 (medium) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBF 1120 twice daily along with standard therapy of PLD + CBDCA
Study: NCT01329549
Drug: BIBF 1120 (low) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBF 1120 twice daily along with standard therapy of PLD + CBDCA
Study: NCT00405808
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily in the morning
Study: NCT01421511
Drug: TR-701 FA
Approvals — FDA: no, EMA: no, PMDA: no
Description: * TR-701 FA 200 mg once daily in 250 mL sterile saline for injection as a 60 minute IV infusion~* TR-701 FA Tablets, 200 mg, orally once daily
Study: NCT00325442
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 0.25, 0.5, 1, or 5 mg oral tablets by mouth every 12 hours
Study: NCT02676349
Drug: mFolfirinox
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxaliplatin folinic acid irinotecan 5FU oxaliplatin
Study: NCT02676349
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine or modified LV5FU (folinic acid+-bolus fluorouracil+ infusional fluorouracil)
Study: NCT01746992
Drug: Cyclophosphamide 750mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: day 1 in both arms
Study: NCT02078323
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01728324
Drug: BI 207127-placebo: 8-week treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 weeks of placebo treatment
Study: NCT01728324
Drug: BI 207127: 24-week treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 weeks of active treatment
Study: NCT01728324
Drug: RBV: 24-week treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 weeks of active treatment
Study: NCT01728324
Drug: BI 207127: 16-week treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 weeks of active treatment
Study: NCT02045277
Drug: IDP-118 Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotion
Study: NCT02045277
Drug: IDP-118 Monad HP Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Comparator
Study: NCT02045277
Drug: IDP-118 Vehicle Lotion
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle
Study: NCT03360981
Drug: Incretins
Approvals — FDA: no, EMA: no, PMDA: no
Description: after CABG, and epicardial tissue biopsy, patients will receive incretin therapy.
Study: NCT00003068
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00158652
Drug: 5FU, Paraplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5FU 600mg/m²/D, Paraplatin 70mg/m²/D In arm 1: D1-4, 3 cycles during Rth (D1, D22, D43) In arm 2: D1-5, 2 cycles during Rth (D1, D29)
Study: NCT01680406
Drug: Artemether-lumefantrine combination
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01340235
Drug: Oral erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Severe Dowling Meara EBS patients from 6 months to 8 years old
Study: NCT02140918
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01056315
Drug: GRT3938Y
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overencapsulated tablets of GRT3983Y, 100 to 300mg daily dose, 16 weeks treatment.
Study: NCT01056315
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overencapsulated tablets of placebo, 16 weeks treatment.
Study: NCT00754715
Drug: AZD2516
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution administered once orally
Study: NCT00754715
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution administered only once
Study: NCT01226407
Drug: CG200745
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple administration (IV) over the cycles untile MTD/LTD
Study: NCT00216021
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 825 mg/m2 po bid, days 1-14
Study: NCT03777579
Drug: JS001，an engineered anti-PD-1 antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: JS001 at a fixed dose of 240 milligrams via intravenous (IV) infusion on Days 1 of each 21-day cycle until disease progression or unacceptable toxicity.
Study: NCT03777579
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered via intravenous (IV) infusion on Days 1 of each 21-day cycle until disease progression or unacceptable toxicity.
Study: NCT04271189
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual medical care to treat diabetes.
Study: NCT02242149
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic Diacerein
Study: NCT04328064
Drug: Rosuvastatin calcium 40mg
Normalized name: Rosuvastatin Calcium 40mg Oral tablet
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Active drug -Rosuvastatin
Study: NCT04328064
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg placebo for 12 months
Study: NCT01423240
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily orally in the evening
Study: NCT01825044
Drug: NeuroSTAT 5 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 5 mg/kg bodyweight/day continuous infusion
Study: NCT01825044
Drug: NeuroSTAT 10 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 10 mg/kg bodyweight/day continuous infusion
Study: NCT01819922
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo powder in capsule, one dose within 5 minutes prior to AM meal
Study: NCT01054404
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (up to 5mL)
Study: NCT01386099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice a day for 12 weeks.
Study: NCT04015908
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 100mg
Study: NCT04015908
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 325mg
Study: NCT01543451
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mg administered s.c. once daily for 4 consecutive days from Day 1 chemotherapy
Study: NCT03769714
Drug: Saline Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 20mL of 0.9%Normal Saline
Study: NCT01140399
Drug: Furosemide or Furosemide and Dopamine
Normalized name: furosemide and potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to pharmacological treatment receive~* either intravenous diuretics at escalating doses up to 20 mg/h~* or intravenous diuretics up to 20 mg/h and dopamine infusion at a constant rate of 3 mcg/Kg/m.
Study: NCT00331786
Drug: nitric oxide-releasing acetylsalicylic acid derivative
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01582152
Drug: TPI287
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I Starting Dose: 160 mg/m2 given by vein on Day 1 every three weeks of a 42 Day cycle.~Phase II Starting Dose: Maximum Tolerated Dose (MTD) from Phase I.
Study: NCT00008294
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00008294
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00008294
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02805907
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00114114
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Androgel placebo or 1.25, 2.5, 5. or 10\* gms topically each day
Study: NCT02237495
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The vehicle of dexmedetomidine, normal saline is continuously infused right after anesthesia induction and lasts for 12 hrs with the same rate of the treatment arm.
Study: NCT02508168
Drug: SYR-322MET
Normalized name: Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYR-322MET (alogliptin 12.5 mg and metformin 1000 mg) fixed-dose combination (FDC) tablets
Study: NCT03593304
Drug: Tablet Pyridoxine hydrochlorid
Normalized name: pyridoxine hydrochloride Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks.
Study: NCT03593304
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection Normal saline(1ml) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.
Study: NCT03593304
Drug: Oral Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Oral Tablet (25 mg) 2 tablets thrice daily for 5 weeks.
Study: NCT00615940
Drug: WX-671
Normalized name: WX-554
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules taken per os once daily until progression or toxicity
Study: NCT00615940
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule taken per os once daily until progression or toxicity
Study: NCT01172288
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 600mg Capsule twice a day for two weeks then 2 600mg capsules twice a day for the remaining 10 weeks of the study. Children receiving placebo will be offered the active intervention after the double-blind portion of the trial.
Study: NCT03288584
Drug: Corticosteroid and non-biological agents.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced treatment with corticosteroid and non-biological agents.
Study: NCT03058458
Drug: PIN201104
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV or SC administration
Study: NCT03058458
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV or SC administration
Study: NCT02436486
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, orally, single dose
Study: NCT02933762
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.
Study: NCT02040441
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02040441
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02040441
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard diabetes care
Study: NCT01017796
Drug: N-acetylcysteine and ascorbic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200mg acetylcysteine and 2g ascorbic acid in 200 ml 0,9% normal saline at least 2 hours before the start of the index procedure, followed by 1200mg acetylcysteine and 1,5g ascorbic acid the night and the morning after the examination.
Study: NCT01536938
Drug: LEO 90100
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02820610
Drug: Normal saline 0.9 %
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg bupivacaine 0.5% diluted in normal saline 0.9 % will instilled into the peritoneal cavity.
Study: NCT01950481
Drug: LDK378
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral LDK378 750 mg once
Study: NCT03393013
Drug: KZR-616
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Injection of KZR-616
Study: NCT00984802
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle solution for IV administration single dose.
Study: NCT02494349
Drug: JLP-1207
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will receive JLP-1207 under fed(high fat meal) condition. After washout period, the subjects will receive Solifenacin 5mg and Tamsulosin 0.2mg under fed(high fat meal) condition.
Study: NCT00374907
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, Oral, 0 mg, Once daily (up to 12 weeks ST)
Study: NCT00856375
Drug: NKTR-102
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV every 3 weeks
Study: NCT04370028
Drug: Divaza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration.
Study: NCT02549677
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide, 600mg per square meter, every 3 weeks, day 1
Study: NCT00698126
Drug: soluble human insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observational study; use of the products as in the normal clinical practice conditions
Study: NCT03395340
Drug: vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching vehicle cream applied as a thin film
Study: NCT00403702
Drug: Oxane HD [oil-RMN3-mixture]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00403702
Drug: Densiron [(F6H8)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01105871
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of normal saline iv bolus
Study: NCT01927198
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01927198
Drug: RDEA3170 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01927198
Drug: RDEA3170 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02082067
Drug: Ketorolac 30mg
Normalized name: ketorolac 30 MG
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00708994
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: • Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes
Study: NCT01927198
Drug: RDEA3170 12.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01915849
Drug: LIK066
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIK066 15 mg, 50 mg and 150 mg
Study: NCT01915849
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02582749
Drug: LHRH agonist/antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treating physician will determine LHRH agonist/antagonist, dosage and route of administration, per package insert, during each 28-day cycle.
Study: NCT00416767
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00416767
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05513612
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered according to package insert
Study: NCT02408146
Drug: fentanyl citrate+ ondansetron hydrochloride + normal saline
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02408146
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04294264
Drug: Trifluridine and Tipiracil Hydrochloride
Normalized name: tipiracil / trifluridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT02858193
Drug: SCMC-lys powder 1.35 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder for oral solution in sachets each containing 1.35 g of S-carboxymethyl-L-cysteine L-lysine monohydrate salt (SCMC-lys).~One sachet of the powder of the test formulation: (1.35 g of SCMC-lys corresponding to 750 mg of carbocysteine-free base) was dissolved in 100 mL of hot (not boiling) still mineral water. Additional 100 mL of still mineral water at room temperature were added and mixed. The solution was swallowed and the glass was rinsed with 40 mL of still mineral water that was also drunk by the subjects. The final administered volume was 240 mL. All subjects were in fasting conditions from the evening before (at least 10 h, overnight).The final administered volume was 240 mL for both the test and reference treatments.
Study: NCT02858193
Drug: Fluifort® syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluifort® 90 mg/mL syrup (15 mL corresponding to 1.35 g SCMC-lys)~Fifteen (15) mL of syrup (1.35 g of SCMC-lys corresponding to 750 mg of carbocysteine-free base) poured in a glass were drunk by the subjects. Afterward, the glass was rinsed twice with a volume of 100 mL and 125 mL of still mineral water and the rinses were drunk immediately by the subjects. The final administered volume was 240 mL for both the test and reference treatments.
Study: NCT02369029
Drug: BAY 1238097
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration twice weekly. Starting dose will be 10 mg per week and dose will be escalated dependent on any dose limiting toxicities.
Study: NCT02461121
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg/kg/d for 2 days
Study: NCT00112151
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 gm gel packets applied once daily. Sham adjustments made during the first 12 weeks. Duration is 52 weeks.
Study: NCT01476215
Drug: Paracetamol medium dissolution suspension
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00288587
Drug: IV loop diuretic
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of conventional diuretic therapy upon hospital admission for treatment of decompensated heart failure.
Study: NCT02082054
Drug: PSE 120 mg, CM 8 mg, Atr 0.36 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.36 mg white, scored, tablets with M27 on scored side and plain on the other side
Study: NCT02082054
Drug: PSE 120 mg, CM 8 mg, Atr 0.24 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.24 mg white, scored, tablets with M27 on scored side and plain on the other side
Study: NCT02082054
Drug: PSE 120 mg, CM 8 mg, Atr 0.12 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.12 mg white, scored, tablets with M27 on scored side and plain on the other side
Study: NCT02082054
Drug: PSE 120 mg, CM 8 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudoephedrine 120 mg, chlorpheniramine 8 mg tablets dosed BID
Study: NCT04755543
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2000 mg/m2 IV continuous infusion over 48 hours from Day 1, Q2W
Study: NCT03919890
Drug: ONO-7684 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT03990766
Drug: Theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline delivered via high-volume, low-pressure nasal saline irrigation
Study: NCT00092586
Drug: Comparator: statins
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01869829
Drug: Observational antifungal therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observational study of primary antifungal therapy utilized and outcomes, including:~fluconazole, voriconazole, amphotericin B, caspofungin, and micafungin~All agents are given as standard of care.
Study: NCT02467452
Drug: BDP/FF/GB
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00366834
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: casopitant placebo
Study: NCT01259492
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator: Placebo
Study: NCT02016417
Drug: A combination of Docetaxel, cisplatin and 5-Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: The TPF regimen consists of docetaxel at a dose of 60 mg/m2/day on day 1, cisplatin 60 mg/m2 by i.v. infusion for 4 h on day 1-3, plus 5-Fluorouracil 600 mg/m2 CIV over 120 hours. The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
Study: NCT00667758
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-5 ml NaCl s.c. on days 1-5